CSL (OTCMKTS:CSLLY) Downgraded to Hold Rating by Royal Bank Of Canada

CSL (OTCMKTS:CSLLY) was downgraded by investment analysts at Royal Bank Of Canada from a “moderate buy” rating to a “hold” rating in a note issued to investors on Wednesday,Zacks.com reports.

Several other research firms also recently weighed in on CSLLY. Zacks Research raised CSL from a “strong sell” rating to a “hold” rating in a research report on Monday, December 29th. Canaccord Genuity Group upgraded CSL from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 28th. One analyst has rated the stock with a Strong Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, CSL currently has an average rating of “Moderate Buy”.

CSL Stock Down 3.7%

Shares of OTCMKTS CSLLY opened at $56.82 on Wednesday. CSL has a 1-year low of $54.10 and a 1-year high of $89.71. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.46 and a quick ratio of 1.12. The business’s 50 day moving average is $59.98 and its two-hundred day moving average is $65.73.

About CSL

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.